Edoardo Poli, Celine Verstuyft, Catherine Guettier, Jean‐Charles Duclos Vallée – 17 November 2020

Haesuk Park, Hyun Jin Song, Xinyi Jiang, Linda Henry, Robert L. Cook, David R. Nelson – 17 November 2020 – Medicaid prior authorization (PA) policies for treatment of hepatitis C virus (HCV) with direct‐acting antiviral (DAA) therapy are changing. We aimed to evaluate effects of changes in PA requirements on treatment uptake and to determine the factors associated with DAA treatment among Florida Medicaid beneficiaries with HCV. This is a retrospective cohort analysis of Florida’s Medicaid administrative claims and electronic medical records (2013‐2018).

The focus of the 2020 AASLD/ASGE Postgraduate Course is the role of endoscopic interventions, and how they may be used to enhance medical and surgical management of patients with hepatobiliary diseases. In an engaging debate format, experts will discuss challenging and sometimes controversial patient cases and topics. Participants are encouraged to interact with faculty during the debates and panel discussions.

Biologic drugs are commonly prescribed for autoimmune conditions and malignancies. How do we manage biologics’ effect on the liver? Acute liver failure has been reported in some patients on TNF-alpha inhibitors. Checkpoint inhibitors that modulate T-cell immune reactivity in cancer are frequently associated with liver injury. This session explores monitoring of liver tests, therapy cessation, corticosteroids and other hot topics.

Review a condensed summary of the clinical research highlights from TLMdX in 2020. This popular debriefing session summarizes all the important findings in clinical hepatology that were presented this year.

With a continuing demand for liver transplantation and a limited organ supply, it is necessary to optimize care at all stages of the transplant continuum. At this timely, informative program, faculty will provide participants with updated information on relevant topics across the transplant process to highlight ways to provide optimal care to transplant patients at all points of their experience.

How can we take steps toward more personalized care of patients living with primary sclerosing cholangitis (PSC)? This intriguing lecture will provide an overview of the latest knowledge on the PSC pathogenesis. Faculty will then expand the discussion to cover potential applications of these advances in the clinic to improve and individualize care of patients with PSC.

This highly anticipated panel discussion provides attendees an exclusive opportunity to hear firsthand from three outstanding leaders in the field. Drs. Harvey J. Alter, Michael Houghton, and Charles M. Rice, the 2020 recipients of the Nobel Prize in Physiology or Medicine, will join TLMdX LIVE for a question and answer session. Their groundbreaking research identified the Hepatitis C virus (HCV) a bloodborne pathogen that causes acute and chronic hepatitis, cirrhosis, and liver cancer and laid the foundation for the future development of a cure.

Hiroshi Ishiba, Yoshio Sumida, Yuya Seko, Saiyu Tanaka, Masato Yoneda, Hideyuki Hyogo, Masafumi Ono, Hideki Fujii, Yuichiro Eguchi, Yasuaki Suzuki, Masashi Yoneda, Hirokazu Takahashi, Takashi Nakahara, Kojiro Mori, Kazuyuki Kanemasa, Keiji Shimada, Kento Imajo, Kanji Yamaguchi, Takumi Kawaguchi, Atsushi Nakajima, Kazuaki Chayama, Toshihide Shima, Kazuma Fujimoto, Takeshi Okanoue, Yoshito Itoh, the Japan Study Group of NAFLD – 16 November 2020 – This study aimed to examine whether the diagnostic accuracy of four noninvasive tests (NITs) for detecting advanced fibrosis in nonalcoholic fatty l

Robert S. Brown – 16 November 2020